Complete response in 12 Out of 12 Patients with Rectal Carcinoma using Immunotherapy

On June 5, published by Cercek et al. in The New England Journal of Medicine, a small trial of 12 patients with stage 2-3 rectal cancer was treated with the PD-1 inhibitor, dostarlimab.   Amazingly, they reported that 12 out of 12 had a complete response. Clearly very exciting and goes with my feeling that … Continue reading Complete response in 12 Out of 12 Patients with Rectal Carcinoma using Immunotherapy